Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Pharmaceutical

Catalyst Pharmaceuticals

Patrick J. McEnany 

Gary Ingenito

Jeff Del Carmen

Preethi Sundaram

Steven R. Miller

Alicia Grande

Brian Elsbernd

The Operations and Strategy team at Catalyst Pharmaceuticals plays a critical role in aligning operational efficiency with strategic goals to enhance patient access to innovative therapies. This multidisciplinary team collaborates on various aspects, including project management, financial analysis, regulatory operations, and manufacturing quality, to ensure the successful development and commercialization of high-quality medicines for rare diseases. They focus on optimizing internal processes, managing partnerships, and driving the overall business strategy to support the company's patient-centric mission.

Operations and Strategy

Medical Affairs and Patient Advocacy

Board and Governance

Leadership Team

Operations and Strategy

About

Team members

Other teams at Catalyst Pharmaceuticals

Medical Affairs and Patient Advocacy

Board and Governance

Leadership Team